Can engineered "designer" T cells outsmart chronic hepatitis B?

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-09-21 DOI:10.1155/2010/901216
U Protzer, H Abken
{"title":"Can engineered \"designer\" T cells outsmart chronic hepatitis B?","authors":"U Protzer, H Abken","doi":"10.1155/2010/901216","DOIUrl":null,"url":null,"abstract":"<p><p>More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered \"designer\" T cells.</p>","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":"2010 ","pages":"901216"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004001/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatitis research and treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2010/901216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2010/9/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered "designer" T cells.

Abstract Image

工程 "设计 "T 细胞能否战胜慢性乙型肝炎?
全球有超过 3.5 亿人持续感染人类乙型肝炎病毒(HBV),有可能发展成肝硬化和肝细胞癌,因此需要长期治疗。虽然疫苗已经问世,新的抗病毒药物也在开发之中,但清除持续感染的细胞仍是一个重大问题。最近在采用细胞疗法方面所做的努力,是通过基因工程 "设计 "T 细胞的生物攻击,对消除 HBV 感染细胞的免疫疗法进行实验性探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信